TG Therapeutics Secures $500M Non-Dilutive Capital, Boosts Share Buyback to $300M
Summary
TG Therapeutics has significantly enhanced its financial position by securing an additional $500 million in non-dilutive capital through an expanded $750 million senior secured credit facility with Blue Owl. This new facility replaces a prior $250 million facility, providing substantial liquidity without shareholder dilution. Concurrently, the company's Board of Directors authorized a material increase to its share repurchase program, expanding it from $100 million to $300 million. This follows the $100 million buyback authorized in late February and signals strong management confidence in the company's valuation and future cash flows, particularly after reporting strong 2025 results and raising 2026 revenue guidance. The non-dilutive financing and expanded buyback are significant positive developments that provide financial flexibility for strategic initiatives and shareholder returns.
At the time of this announcement, TGTX was trading at $30.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $25.28 to $46.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.